Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 62

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 62
---
 will receive a pro-ratedtarget annual bonus. Mr. McFarlane is also subject to 12-month post-termination non-competitionand non-solicitationrestrictions. Adrian Quartel, M.D., PPFM In January 2024, we entered into an employment agreement with Dr. Quartel under which he serves as our Chief Medical Officer (the “Quartel Agreement”). Pursuant to the Quartel Agreement, Dr. Quartel is entitled to (i) an initial annual base salary of $485,000, (ii) an annual performance-basedtarget bonus of 40% of his annual base salary and (iii) an initial award of an option to purchase 300,000 shares of the Company’s common stock, which was granted to him in January 2024. Upon a termination of Dr. Quartel’s employment without cause by the Company or resignation for good reason, Dr. Quartel is entitled to receive (a) an amount equal to 12 months of his annual base salary, less applicable deductions, payable in accordance with our normal payroll schedule, (b) a pro-ratedtarget annual bonus for the year in which termination occurs, (c) 12 months of Company-paidCOBRA continuation coverage, and (d) full vesting of his outstanding and unvested equity awards, except that if such termination occurs within one year following a sale that constitutes a “change in control event” as defined in Section 409A of the Code, then in lieu of the payment described in clause (a), Dr. Quartel will be entitled to a lump sum payment equal to 1.0 times his annual base salary. Upon Dr. Quartel’s termination due to death or disability, Dr. Quartel will receive a pro-ratedtarget annual bonus. Dr. Quartel is also subject to 12-month post-termination non-competitionand 61 non-solicitationrestrictions. Under the terms of the Quartel Agreement, if we undergo a change of control, all then unvested and outstanding equity awards will become fully vested and immediately exercisable immediately prior to such change in control. R. LaDuane Clifton, MBA, CPA In 2015, we entered into an amended and restated employment agreement with Mr. Clifton under which he serves as our Chief Financial Officer (as amended, the “Clifton Agreement”). Pursuant to the Clifton Agreement, Mr. Clifton is entitled to (i) an annual base salary and (ii) an annual performance-basedbonus